{"brief_title": "Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease", "brief_summary": "OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.", "detailed_description": "PROTOCOL OUTLINE: Patients receive magnesium sulfate IV over 1 hour on day 3. Patients then receive oral magnesium gluconate supplementation daily. Treatment with magnesium sulfate repeats once at 3-6 months.", "condition": "Biliary Atresia", "intervention_type": "Drug", "intervention_name": "magnesium sulfate", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Diagnosis of liver disease with chronic cholestasis Nonsyndromic intrahepatic cholestasis Alagille's syndrome Extrahepatic biliary atresia - Direct bilirubin greater than 2 mg/dL OR Bile acids greater than 20 micromoles/L - No hepatic decompensation defined as one or more of the following: Ascites Peripheral edema PT at least 4 seconds longer than control Albumin less than 3 g/dL --Patient Characteristics-- - Renal: No significant renal disease - Cardiovascular: No significant cardiovascular disease - Pulmonary: No significant pulmonary disease", "gender": "All", "minimum_age": "3 Years", "maximum_age": "18 Years", "healthy_volunteers": "No", "id": "NCT00007033.xml"}